Ceftazidime Breakpoints against Stenotrophomonas Maltophilia

U.S. Food and Drug Administration sent this bulletin at 05/15/2024 04:16 PM EDT

If your email program has trouble displaying this email, view as a webpage.

FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria

May 15, 2024

FDA concurs with CLSI to remove STIC (MIC) for S. maltophilia for Ceftazidime. Rationale

For additional information about the FDA susceptibility test interpretive criteria recognition please visit http://www.fda.gov/STIC.

** If you did not subscribe to the FDA Recognized Antimicrobial STIC Breakpoints subscription you may unsubscribe from this list by clicking on the "Manage Preferences or Unsubscribe from this List" link below.

Manage Subscriptions | Unsubscribe All | Help